Douglas Tsao
Stock Analyst at H.C. Wainwright
(4.92)
# 210
Out of 4,504 analysts
1222
Total ratings
57.9%
Success rate
25.7%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Reiterated: Hold | $43 | $51.25 | -16.10% | 58 | Jul 13, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | $15 → $17 | $16.93 | +0.41% | 40 | Jul 7, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | $81 → $85 | $83.66 | +1.60% | 64 | Jul 7, 2026 | |
| PCRX Pacira BioSciences | Reiterated: Buy | $38 | $25.74 | +47.63% | 29 | Jul 1, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $22 | $19.14 | +14.94% | 30 | Jun 29, 2026 | |
| STO: HNSA Hansa Biopharma AB (publ) | Maintained: Buy | kr 103.00 | $33.68 | +205.82% | 51 | Jun 29, 2026 | |
| ARGX argenx SE | Maintained: Buy | $940 | $872.74 | +7.71% | 65 | Jun 25, 2026 | |
| NMRA Neumora Therapeutics | Reiterated: Buy | $18 → $7 | $1.57 | +347.28% | 23 | Jun 16, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $5 | $4.77 | +4.93% | 45 | Jun 15, 2026 | |
| CABA Cabaletta Bio | Reiterated: Buy | n/a | $2.80 | - | 50 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $74.53 | - | 37 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,201 | $314.93 | +281.35% | 55 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $15.37 | -34.94% | 21 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $38.69 | +3.39% | 45 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $34.84 | -2.40% | 45 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.12 | +466.04% | 40 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.49 | +371.38% | 77 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $4.54 | +54.19% | 43 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $117 | $129.15 | -9.40% | 78 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $26.91 | +26.35% | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 | $67.07 | +10.33% | 16 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $6.38 | +103.92% | 56 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.5 | $1.57 | -68.05% | 47 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $40.51 | -1.26% | 10 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.78 | +151.80% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $125 → $5 | $0.011 | n/a | 26 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $360 | $0.4101 | n/a | 9 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $0.00001 | n/a | 13 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $13.28 | n/a | 4 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.03 | n/a | 19 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €19.00 → €11.00 | $3.74 | n/a | 7 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $23 | $32.66 | n/a | 12 | Aug 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $31 → $33 | $32.30 | n/a | 2 | Jul 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $93 → $80 | $10.27 | n/a | 8 | Jun 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $6.91 | n/a | 17 | Jun 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $17.25 | n/a | 2 | May 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $71 → $77 | $75.31 | n/a | 6 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $108 → $120 | $166.89 | n/a | 12 | Oct 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $120 | $211.42 | n/a | 3 | Oct 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $76.45 | n/a | 3 | Jun 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $47 → $50 | $16.41 | n/a | 6 | May 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 | $238.84 | n/a | 7 | Jan 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $234.73 | n/a | 5 | Nov 30, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $14 → $2 | $6.72 | n/a | 5 | Nov 16, 2016 |
Alkermes
Jul 13, 2026
Reiterated: Hold
Price Target: $43
Current: $51.25
Upside: -16.10%
Theravance Biopharma
Jul 7, 2026
Downgraded: Hold
Price Target: $15 → $17
Current: $16.93
Upside: +0.41%
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: $81 → $85
Current: $83.66
Upside: +1.60%
Pacira BioSciences
Jul 1, 2026
Reiterated: Buy
Price Target: $38
Current: $25.74
Upside: +47.63%
Viridian Therapeutics
Jun 29, 2026
Reiterated: Buy
Price Target: $22
Current: $19.14
Upside: +14.94%
Hansa Biopharma AB (publ)
Jun 29, 2026
Maintained: Buy
Price Target: kr 103.00
Current: $33.68
Upside: +205.82%
argenx SE
Jun 25, 2026
Maintained: Buy
Price Target: $940
Current: $872.74
Upside: +7.71%
Neumora Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $18 → $7
Current: $1.57
Upside: +347.28%
Rezolute
Jun 15, 2026
Reiterated: Buy
Price Target: $5
Current: $4.77
Upside: +4.93%
Cabaletta Bio
Jun 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.80
Upside: -
Jun 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $74.53
Upside: -
Jun 8, 2026
Maintained: Buy
Price Target: $1,201
Current: $314.93
Upside: +281.35%
Jun 1, 2026
Reiterated: Hold
Price Target: $10
Current: $15.37
Upside: -34.94%
May 26, 2026
Reiterated: Buy
Price Target: $40
Current: $38.69
Upside: +3.39%
May 21, 2026
Reiterated: Buy
Price Target: $34
Current: $34.84
Upside: -2.40%
May 15, 2026
Reiterated: Buy
Price Target: $12
Current: $2.12
Upside: +466.04%
May 12, 2026
Reiterated: Buy
Price Target: $7
Current: $1.49
Upside: +371.38%
May 11, 2026
Reiterated: Hold
Price Target: $7
Current: $4.54
Upside: +54.19%
May 11, 2026
Reiterated: Buy
Price Target: $117
Current: $129.15
Upside: -9.40%
May 11, 2026
Reiterated: Buy
Price Target: $34
Current: $26.91
Upside: +26.35%
May 8, 2026
Reiterated: Buy
Price Target: $74
Current: $67.07
Upside: +10.33%
May 5, 2026
Maintained: Buy
Price Target: $13
Current: $6.38
Upside: +103.92%
Apr 8, 2026
Reiterated: Hold
Price Target: $0.5
Current: $1.57
Upside: -68.05%
Mar 11, 2026
Reiterated: Buy
Price Target: $40
Current: $40.51
Upside: -1.26%
Nov 6, 2025
Reiterated: Buy
Price Target: $7
Current: $2.78
Upside: +151.80%
Nov 14, 2024
Downgraded: Hold
Price Target: $125 → $5
Current: $0.011
Upside: n/a
Oct 1, 2024
Reiterated: Buy
Price Target: $360
Current: $0.4101
Upside: n/a
Aug 21, 2023
Reiterated: Buy
Price Target: $4 → $3
Current: $0.00001
Upside: n/a
Mar 8, 2023
Maintained: Hold
Price Target: $6
Current: $13.28
Upside: n/a
Nov 30, 2022
Rated: Hold
Price Target: n/a
Current: $2.03
Upside: n/a
Nov 1, 2022
Reiterated: Buy
Price Target: €19.00 → €11.00
Current: $3.74
Upside: n/a
Aug 6, 2018
Maintained: Hold
Price Target: $23
Current: $32.66
Upside: n/a
Jul 3, 2018
Maintained: Sell
Price Target: $31 → $33
Current: $32.30
Upside: n/a
Jun 6, 2018
Downgraded: Hold
Price Target: $93 → $80
Current: $10.27
Upside: n/a
Jun 6, 2018
Upgraded: Buy
Price Target: n/a
Current: $6.91
Upside: n/a
May 1, 2018
Initiated Coverage: Buy
Price Target: $27
Current: $17.25
Upside: n/a
Feb 16, 2018
Maintained: Hold
Price Target: $71 → $77
Current: $75.31
Upside: n/a
Oct 27, 2017
Maintained: Hold
Price Target: $108 → $120
Current: $166.89
Upside: n/a
Oct 27, 2017
Reiterated: Buy
Price Target: $100 → $120
Current: $211.42
Upside: n/a
Jun 22, 2017
Maintained: Buy
Price Target: $16
Current: $76.45
Upside: n/a
May 22, 2017
Upgraded: Buy
Price Target: $47 → $50
Current: $16.41
Upside: n/a
Jan 18, 2017
Maintained: Buy
Price Target: $200
Current: $238.84
Upside: n/a
Nov 30, 2016
Upgraded: Hold
Price Target: n/a
Current: $234.73
Upside: n/a
Nov 16, 2016
Reiterated: Sell
Price Target: $14 → $2
Current: $6.72
Upside: n/a